Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases
Authors
Paz-Ares, LDziadziuszko, R
Drilon, A
John, T
Krebs, Matthew G
Demetri, G
Shaw, AT
Siena, S
Wolf, J
Farago, AF
Simmons, B
Pitcher, B
Huang, XH
Doebele, R
Affiliation
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid,Issue Date
2020